{"id":"W2295530774","doi":"10.3324/haematol.2015.135418","title":"Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial","year":2016,"lang":"en","type":"letter","venue":"Haematologica","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"ca_institutions":"Toronto East General Hospital; Sunnybrook Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"Leukemia and Lymphoma Society of Canada; University of Toronto; Leukemia and Lymphoma Society","keywords":"Ruxolitinib; Idelalisib; Janus kinase; Myelofibrosis; Venetoclax; Medicine; Chronic lymphocytic leukemia; Ibrutinib; Oncology; STAT protein; Internal medicine; Janus kinase 1; Clinical trial; stat; Clinical endpoint; Cancer research; Tolerability; STAT3; Leukemia; Signal transduction; Chemistry; Adverse effect; Receptor; Bone marrow","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001110566,0.0006764985,0.00261413,0.0004678233,0.0001162416,0.00001372289,0.0009648923,0.002096175,0.0002381582],"category_scores_gemma":[0.003153115,0.000381062,0.0007867721,0.0007234257,0.001341094,0.0000892126,0.0008852846,0.002097924,0.00004986729],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.08504891,"about_ca_system_score_gemma":0.07700219,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002073592,"about_ca_topic_score_gemma":0.00008622481,"domain_scores_codex":[0.9935526,0.0007279603,0.001777542,0.001069716,0.001617022,0.001255207],"domain_scores_gemma":[0.994089,0.001717055,0.001345509,0.002396939,0.0002908282,0.00016069],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1511354,0.0008686632,0.000006303547,0.007215541,0.0004661652,0.01190272,0.0004573716,0.00001230593,0.01109516,0.0001159314,0.8091332,0.007591263],"study_design_scores_gemma":[0.6766503,0.007750878,0.00001761012,0.005311877,0.0003591494,0.001484377,0.0000218105,0.0009524267,0.1013578,0.0002602937,0.2052394,0.0005940896],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.928566,0.0007233089,0.00000478395,0.06006345,0.0007600832,0.004146463,0.0005457854,0.00007817121,0.005111957],"genre_scores_gemma":[0.9788432,0.0002193659,0.00004363382,0.01299002,0.002906438,0.0003455575,0.00009603145,0.00009605511,0.004459691],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6038938,"threshold_uncertainty_score":0.9998641,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04686190938523953,"score_gpt":0.3334470027006804,"score_spread":0.2865850933154409,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}